Patents by Inventor Nolwenn Martin
Nolwenn Martin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Amorphous solid dispersion of an orally available gonadotropin-releasing hormone receptor antagonist
Patent number: 10966979Abstract: The invention relates to an amorphous solid dispersion comprising elagolix sodium and at least one silicon-based inorganic compound and to a process for preparing the same. Furthermore, it relates to a pharmaceutical composition comprising said solid dispersion and one or more additional pharmaceutical acceptable excipient(s), wherein the pharmaceutical composition can be used as a medicament, in particular for the treatment of endometriosis and uterine fibroids.Type: GrantFiled: April 11, 2018Date of Patent: April 6, 2021Assignee: Sandoz AGInventor: Nolwenn Martin -
Patent number: 10961235Abstract: The present invention relates to a polymorphic form of masitinib mesylate, processes for its preparation, pharmaceutical compositions comprising it and their medical use.Type: GrantFiled: March 22, 2018Date of Patent: March 30, 2021Inventors: Nolwenn Martin, Diana Fischer-Daut
-
Publication number: 20210087175Abstract: The present invention relates to a crystalline form of darolutamide and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline form of darolutamide, preferably in a predetermined and/or effective amount, and at least one pharmaceutically acceptable excipient. The present invention also relates to 5 pharmaceutical compositions comprising darolutamide at a high drug load. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of prostate cancer.Type: ApplicationFiled: February 25, 2019Publication date: March 25, 2021Applicant: Sandoz AGInventors: Verena Adamer, Nolwenn Martin, Andrea Thaler, Veronika Werner, Johannes Raneburger, Franz Xaver Schwarz, Igor Legen, Rebeka Jereb
-
Publication number: 20210046096Abstract: The present invention relates to a solid dispersion comprising amorphous brigatinib and methods for preparing the same. The invention also concerns a pharmaceutical composition comprising an effective amount of said solid dispersion and at least one further pharmaceutically acceptable excipient as well as methods for its preparation. The pharmaceutical composition of the present invention may be used as a medicine in particular for the treatment of ALK (anaplastic lymphoma kinase)-positive metastatic non-small cell lung cancer (NSCLC) and other diseases.Type: ApplicationFiled: February 7, 2019Publication date: February 18, 2021Applicant: Sandoz AGInventor: Nolwenn Martin
-
Publication number: 20200102297Abstract: The present invention relates to a polymorphic form of masitinib mesylate, processes for its preparation, pharmaceutical compositions comprising it and their medical use.Type: ApplicationFiled: March 22, 2018Publication date: April 2, 2020Applicant: Sandoz AGInventors: Nolwenn Martin, Diana Fischer-Daut
-
Amorphous Solid Dispersion Of An Orally Available Gonadotropin-Releasing Hormone Receptor Antagonist
Publication number: 20200022980Abstract: The invention relates to an amorphous solid dispersion comprising elagolix sodium and at least one silicon-based inorganic compound and to a process for preparing the same. Furthermore, it relates to a pharmaceutical composition comprising said solid dispersion and one or more additional pharmaceutical acceptable excipient(s), wherein the pharmaceutical composition can be used as a medicament, in particular for the treatment of endometriosis and uterine fibroids.Type: ApplicationFiled: April 11, 2018Publication date: January 23, 2020Applicant: Sandoz AGInventor: Nolwenn Martin -
Publication number: 20190381085Abstract: A solid composition comprising sofosbuvir and at least one pharmaceutically acceptable matrix compound wherein at least 99 weight-% of the sofosbuvir comprised in the composition are present in amorphous form, at least 99 weight-% of the solid composition consist of the sofosbuvir and the at least one matrix compound, and wherein the solid composition contains the sofosbuvir in an amount of at least 55 weight-% based on the combined weight of the sofosbuvir and the at least one matrix compound.Type: ApplicationFiled: August 23, 2019Publication date: December 19, 2019Applicant: Sandoz AGInventor: Nolwenn Martin
-
Patent number: 10493089Abstract: A solid composition comprising sofosbuvir and at least one pharmaceutically acceptable matrix compound wherein at least 99 weight-% of the sofosbuvir comprised in the composition are present in amorphous form, at least 99 weight-% of the solid composition consist of the sofosbuvir and the at least one matrix compound, and wherein the solid composition contains the sofosbuvir in an amount of at least 55 weight-% based on the combined weight of the sofosbuvir and the at least one matrix compound.Type: GrantFiled: April 2, 2015Date of Patent: December 3, 2019Assignee: Sandoz AGInventor: Nolwenn Martin
-
Publication number: 20180271890Abstract: A solid pharmaceutical composition comprising a solid composition, wherein the solid com-position comprises sofosbuvir and at least one pharmaceutically acceptable matrix compound, wherein at least 99 weight-% of the sofosbuvir comprised in the solid composition are present in amorphous form, at least 99 weight-% of the solid composition consist of the sofosbuvir and the at least one matrix compound, wherein the solid composition contains the sofosbuvir in an amount of at least 25 weight-%, or at least 30 weight-%, or at least 35 weight-%, or at least 40 weight-% or at least 50 weight-% or at least 55 weight-% or preferably at least 5 weight-% based on the combined weight of the sofosbuvir and the at least one matrix com-pound, wherein in the adsorption-desorption isotherm of the at least one pharmaceutically acceptable matrix compound, the desorption mass difference minus the adsorption mass dif-ference at 75% relative humidity and 25° C. is less than 0.Type: ApplicationFiled: October 6, 2016Publication date: September 27, 2018Applicant: Sandoz AGInventors: Franz Xaver SCHWARZ, Nolwenn MARTIN
-
Publication number: 20180008624Abstract: The present invention relates to novel pharmaceutical compositions comprising Ledipasvir and Sofosbuvir as well as to methods for their preparation.Type: ApplicationFiled: February 10, 2016Publication date: January 11, 2018Applicant: Sandoz AGInventors: Franz Xaver Schwarz, Georg ANKER, Nolwenn MARTIN
-
Publication number: 20170296570Abstract: A tablet comprising a polymorphic form of crystalline sofosbuvir having a moisture stability of at least 95% in an amount of at least 40 weight-%.Type: ApplicationFiled: October 8, 2015Publication date: October 19, 2017Applicant: Sandoz AGInventors: Nolwenn Martin, Franz Schwarz, Georg Anker
-
Publication number: 20170100422Abstract: A solid composition comprising sofosbuvir and at least one pharmaceutically acceptable matrix compound wherein at least 99 weight-% of the sofosbuvir comprised in the composition are present in amorphous form, at least 99 weight-% of the solid composition consist of the sofosbuvir and the at least one matrix compound, and wherein the solid composition contains the sofosbuvir in an amount of at least 55 weight-% based on the combined weight of the sofosbuvir and the at least one matrix compound.Type: ApplicationFiled: April 2, 2015Publication date: April 13, 2017Applicant: SANDOZ AGInventor: Nolwenn MARTIN
-
Patent number: 9534004Abstract: The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation. Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and ?-lactamase inhibitors.Type: GrantFiled: December 19, 2013Date of Patent: January 3, 2017Assignee: SANDOZ AGInventors: Josef Wieser, Hubert Sturm, Arthur Pichler, Andreas Hotter, Nolwenn Martin, Christoph Langes, Ulrich Griesser
-
Publication number: 20160200750Abstract: The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation. Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and ?-lactamase inhibitors.Type: ApplicationFiled: December 19, 2013Publication date: July 14, 2016Inventors: Josef Wieser, Hubert Sturm, Arthur Pichler, Andreas Hotter, Nolwenn Martin, Christoph Langes, Ulrich Griesser
-
Publication number: 20090030216Abstract: The invention relates to a method for producing chiral organic compounds by asymmetric catalysis, using ionic catalysts comprising a chiral catalyst anion. The claimed method is suitable for reactions which are carried out over cationic intermediate stages, such as iminium ions or acyl pyridinium ions. The invention enables the production of chiral compounds with high ee values, that until now could only be obtained by means of costly purification methods.Type: ApplicationFiled: February 27, 2007Publication date: January 29, 2009Applicant: STUDIENGESELLSCHAFT KOHLE MBHInventors: Benjamin List, Sonja Mayer, Nolwenn Martin, Xingwang Wang